CF
ANIK icon

Corebridge Financial’s Anika Therapeutics ANIK Stock Holding History

Corebridge Financial’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,351
Closed -$95.5K – 174
2025
Q1 		$95.5K Sell
6,351
-185
-3% -$3.08K ﹤0.01% 2460
2024
Q4 		$108K Sell
6,536
-493
-7% -$9.72K ﹤0.01% 2513
2024
Q3 		$174K Sell
7,029
-850
-11% -$22K ﹤0.01% 2298
2024
Q2 		$200K Buy
+7,879
New +$204K ﹤0.01% 2196

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return

Corebridge Financial's ANIK Position: Q2 2025 in Review

Corebridge Financial sold out of Anika Therapeutics (ANIK) in Q2 2025, closing a stake of 6,351 shares — an estimated $95.5K sold.

Corebridge Financial first reported a position in ANIK in Q2 2024 and held it in 4 quarters. The position peaked at $200K in Q2 2024. 103 funds tracked by Wall St. Rank hold ANIK as of Q2 2025.

  • Corebridge Financial reported no remaining Anika Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 6,351 Anika Therapeutics shares in Q2 2025, an estimated $95.5K.
  • Corebridge Financial first reported a position in Anika Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Anika Therapeutics position peaked at $200K in Q2 2024.
  • 103 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.